This is a revised application from the William Dameshek Division of Hematology/Oncology at Tufts Medical Center for competitive renewal of our long-standing training grant, T32 CA09429, entitled "Research Training in Oncology". The long-term objective of the application has not changed, which is to continue the training and mentoring of physicians in the Hematology/Oncology Division Fellowship Program in basic and translational cancer science, in order to prepare them for independent careers in academic hematology/oncology. The program is based in the Division of Hematology/Oncology at Tufts Medical Center (Tufts MC), the principal teaching hospital for Tufts University School of Medicine (TUSM). The training program is a highly structured research experience that is centered around laboratory investigation within the research group of a faculty mentor. The laboratory component is complimented by formal coursework, other didactic training, and participation in seminars, workshops, and meetings. The progress of each trainee is closely monitored by a research committee. The Program currently has 26 research faculty mentors drawn from members of the Division and from other clinical and basic science departments at Tufts MC and TUSM, a significant increase from 19 Program faculty in the last competitive renewal in 2002. This reflects a new emphasis on cancer in the strategic plans of Tufts MC and TUSM, leading to the establishment of the Molecular Oncology Research Institute, and a major institutional effort to obtain National Cancer Institute Comprehensive Cancer Center designation for the Tufts Medical Center Cancer Center. The Program faculty mentors represent a major strength of the application, and are carefully selected on the basis of their training record and for their specific research interests in neoplasia, which span the spectrum from oncogenes and tumor suppressors, signal transduction, cell cycle regulation and apoptosis, angiogenesis and metastasis, animal models of hematologic malignancies and solid tumors, and preclinical testing of molecularly targeted cancer therapeutics. This training Program has been highly successful in preparing our fellows for careers in academic oncology. Former trainees now head major departments in academia and in NCI designated cancer centers, are on faculty at academic institutions in the US and elsewhere, and hold senior management positions in the oncology pharmaceutical field.

Public Health Relevance

The treatment of cancer has been revolutionized over the past ten years through the development of drugs that specifically target cancer cells. The United States has a great need for cancer doctors who work at the interface between cancer patients and experimental treatments, and who can discover and apply the next generation of therapies. This grant application will support the training of such physicians at Tufts Medical Center, continuing a program that has generated leaders in this field for more than a quarter century.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Tufts University
United States
Zip Code
Shah, Gunjan L; Rosenberg, Aaron S; Jarboe, Jamie et al. (2014) Incidence and evaluation of incidental abnormal bone marrow signal on magnetic resonance imaging. ScientificWorldJournal 2014:380814
Kaimal, Rajani; Aljumaily, Raid; Tressel, Sarah L et al. (2013) Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 73:2457-67
Ahmed, Wesam; Van Etten, Richard A (2013) Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep 8:71-80
Jun, H J; Acquaviva, J; Chi, D et al. (2012) Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 31:3039-50
Walz, Christoph; Ahmed, Wesam; Lazarides, Katherine et al. (2012) Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 119:3550-60
Jeselsohn, Rinath; Brown, Nelson E; Arendt, Lisa et al. (2010) Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 17:65-76
Mao, Changchuin; Tili, Esmerina G; Dose, Marei et al. (2007) Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol 178:5443-53
Savvides, Panos; Terrin, Norma; Erban, John et al. (2003) Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Support Care Cancer 11:313-20
Modrak, D E; Draper, M P; Levy, S B (1997) Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines. Biochem Pharmacol 54:1297-306
Draper, M P; Martell, R L; Levy, S B (1997) Active efflux of the free acid form of the fluorescent dye 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. Eur J Biochem 243:219-24

Showing the most recent 10 out of 26 publications